Products and Services
The Seromic™ Profiling Assay enables the detection of changes in serum antibody content against multiple antigens simultaneously. This innovative technology is proving highly valuable to clinicians and pharmaceutical companies for early detection of disease, patient selection, the prediction and monitoring of drug reactions, drug repurposing and applications in translational medicine.
In The News
SAN DIEGO, CA, April 16, 2012 -- Penn State Hershey Children’s Hospital and Serametrix will collaborate on developing a diagnostic test for predicting individual clinical response to a novel immune therapy for brain cancer, it was announced today. The serum-based test is designed to determine patient immune responses from cancer immunotherapy, enabling clinicians to determine in the future which patients...
New Disease Panels now available!
Serametrix continues to develop new and exciting assays for early detection and companion diagnostics. Most recently, we have added panels for glioblastoma, renal cell carcinoma and non small cell lung cancer. For more information, email email@example.com or click on the links below: